Table of Contents
ISRN Oncology
Volume 2012, Article ID 890310, 7 pages
http://dx.doi.org/10.5402/2012/890310
Research Article

Estrogen Abolishes Protective Effect of Erythropoietin against Cisplatin-Induced Nephrotoxicity in Ovariectomized Rats

1Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan 81745, Iran
2Department of Physiology, Isfahan University of Medical Sciences, Isfahan 81745, Iran
3Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan 81745, Iran
4Department of Clinical Pathology, Isfahan University of Medical Sciences, Isfahan 81745, Iran
5Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan 81745, Iran

Received 26 September 2012; Accepted 12 October 2012

Academic Editors: M. Stracke and Y. Yu

Copyright © 2012 Zahra Pezeshki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Arany and R. L. Safirstein, “Cisplatin nephrotoxicity,” Seminars in Nephrology, vol. 23, no. 5, pp. 460–464, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. R. P. Miller, R. K. Tadagavadi, G. Ramesh, and W. B. Reeves, “Mechanisms of cisplatin nephrotoxicity,” Toxins, vol. 2, no. 11, pp. 2490–2518, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Y. Saad and A. C. Al-Rikabi, “Protection effects of taurine supplementation against cisplatin-induced nephrotoxicity in rats,” Chemotherapy, vol. 48, no. 1, pp. 42–48, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Nowak, “Protein kinase C-α and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells,” The Journal of Biological Chemistry, vol. 277, no. 45, pp. 43377–43388, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. X. Yao, K. Panichpisal, N. Kurtzman, and K. Nugent, “Cisplatin nephrotoxicity: a review,” American Journal of the Medical Sciences, vol. 334, no. 2, pp. 115–124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Saleh, A. A. Ain-Shoka, E. El-Demerdash, and M. M. Khalef, “Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury,” Chemotherapy, vol. 55, no. 6, pp. 399–406, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Eshraghi-Jazi, M. Nematbakhsh, H. Nasri et al., “The protective role of endogenous nitric oxide donor (L-arginine) in cisplatin-induced nephrotoxicity: gender related differences in rat model,” Journal of Research in Medical Sciences, vol. 16, no. 11, pp. 1389–1396, 2011. View at Google Scholar · View at Scopus
  8. B. H. Ali and M. S. Al Moundhri, “Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research,” Food and Chemical Toxicology, vol. 44, no. 8, pp. 1173–1183, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Bagnis, H. Beaufils, C. Jacquiaud et al., “Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat,” Nephrology Dialysis Transplantation, vol. 16, no. 5, pp. 932–938, 2001. View at Google Scholar · View at Scopus
  10. H. E. Mohamed, S. E. El-Swefy, R. H. Mohamed, and A. M. Ghanim, “Effect of erythropoietin therapy on the progression of cisplatin induced renal injury in rats,” Experimental and Toxicologic Pathology. In press. View at Publisher · View at Google Scholar
  11. D. A. Vesey, C. Cheung, B. Pat, Z. Endre, G. Gobé, and D. W. Johnson, “Erythropoietin protects against ischaemic acute renal injury,” Nephrology Dialysis Transplantation, vol. 19, no. 2, pp. 348–355, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. E. J. Sharples, N. Patel, P. Brown et al., “Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion,” Journal of the American Society of Nephrology, vol. 15, no. 8, pp. 2115–2124, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Kong, L. Zhuo, C. Gao, S. Shi, N. Wang, Z. Huang et al., “Erythropoietin protects against cisplatin-induced nephrotoxicity by attenuating endoplasmic reticulum stress-inducedapoptosis,” Journal of Nephrology. In press. View at Publisher · View at Google Scholar
  14. K. Rjiba-Touati, I. A. Boussema, A. Belarbia, A. Achour, and H. Bacha, “Protective effect of recombinant human erythropoietin against cisplatin-induced oxidative stress and nephrotoxicity in rat kidney,” International Journal of Toxicology, vol. 30, no. 5, pp. 510–517, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Zafirov, G. Petrusevska, A. Sikole et al., “Erythropoietin reduces cumulative nephrotoxicity from cisplatin and enhances renal tubular cell proliferation,” Prilozi, vol. 29, no. 2, pp. 167–183, 2008. View at Google Scholar · View at Scopus
  16. S. Yalcin, S. Müftüoǧlu, E. Cetin et al., “Protection against cisplatin-induced nephrotoxicity by recombinant human erythropoietin,” Medical Oncology, vol. 20, no. 2, pp. 169–173, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Rafieian-Kopaei, H. Nasri, M. Nematbakhsh, A. Baradaran, GheissariA, H. Rouhi et al., “Erythropoietin ameliorates genetamicin-induced renal toxicity: a biochemical and histopathological study,” Journal of Nephropathology, vol. 1, no. 2, pp. 109–116, 2012. View at Google Scholar
  18. D. W. Johnson, D. A. Vesey, and G. C. Gobe, “Erythropoietin protects against acute kidney injury and failure,” Open Drug Discovery Journal, vol. 2, no. 1, pp. 8–17, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Peschle, I. A. Rappaport, G. F. Sasso, M. Condorelli, and A. S. Gordon, “The role of estrogen in the regulation of erythropoietin production,” Endocrinology, vol. 92, no. 2, pp. 358–362, 1973. View at Google Scholar · View at Scopus
  20. H. Mukundan, T. C. Resta, and N. L. Kanagy, “17β-estradiol decreases hypoxic induction of erythropoietin gene expression,” American Journal of Physiology, vol. 283, no. 2, pp. R496–R504, 2002. View at Google Scholar · View at Scopus
  21. S. Y. Saad, T. A. O. Najjar, M. H. Daba, and A. C. Al-Rikabi, “Inhibition of nitric oxide synthase aggravates cisplatin-induced nephrotoxicity: effect of 2-amino-4-methylpyridine,” Chemotherapy, vol. 48, no. 6, pp. 309–315, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Moore and R. Bellomo, “Erythropoietin, (EPO) in acute kidney injury,” Annals of Intensive Care, vol. 1, no. 1, p. 3, 2011. View at Publisher · View at Google Scholar
  23. K. Rjiba-Touati, I. Ayed-Boussema, C. Bouaziz et al., “Protective effect of erythropoietin against cisplatin-induced nephrotoxicity in rats: antigenotoxic and antiapoptotic effect,” Drug and Chemical Toxicology, vol. 35, no. 1, pp. 89–95, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. D. W. Lee, I. S. Kwak, S. B. Lee et al., “Post-treatment effects of erythropoietin and nordihydroguaiaretic acid on recovery from cisplatin-induced acute renal failure in the rat,” Journal of Korean medical science, vol. 24, supplement 1, pp. S170–S175, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Li, D. A. Vesey, D. W. Johnson, and G. Gobe, “Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway,” Cancer Biology and Therapy, vol. 6, no. 12, pp. 1944–1950, 2007. View at Google Scholar · View at Scopus
  26. N. D. Vaziri, X. J. Zhou, and S. Y. Liao, “Erythropoietin enhances recovery from cisplatin-induced acute renal failure,” American Journal of Physiology, vol. 266, no. 3, part 2, pp. F360–F366, 1994. View at Google Scholar · View at Scopus
  27. D. Stakišaitis, G. Dudeniene, R. J. Jankunas, G. Graželiene, J. Didžiapetriene, and B. Pundziene, “Cisplatin increases urinary sodium excretion in rats: gender-related differences,” Medicina, vol. 46, no. 1, pp. 45–50, 2010. View at Google Scholar · View at Scopus
  28. M. Nematbakhsh, A. Talebi, H. Nasri, T. Safari, S. Dolatkhah, F. Ashrafi et al., “Some evidence for sex-based differences in cisplatin-induced nephrotoxicity in rats,” Clinical and Experimental Medical Letters, vol. 53, no. 1-229, 31 pages, 2012. View at Google Scholar
  29. M. A. Beleh, Y. C. Lin, and R. W. Brueggemeier, “Estrogen metabolism in microsomal, cell, and tissue preparations of kidney and liver from Syrian hamsters,” Journal of Steroid Biochemistry and Molecular Biology, vol. 52, no. 5, pp. 479–489, 1995. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Roy and J. G. Liehr, “Target organ-specific inactivation of drug metabolizing enzymes in kidney of hamsters treated with estradiol,” Molecular and Cellular Biochemistry, vol. 110, no. 1, pp. 31–39, 1992. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Butterworth, S. S. Lau, and T. J. Monks, “2-Hydroxy-4-glutathion-S-yl-17β-estradiol and 2-hydroxy-1-glutathion-S-yl-17β-estradiol produce oxidative stress and renal toxicity in an animal model of 17β-estradiol-mediated nephrocarcinogenicity,” Carcinogenesis, vol. 19, no. 1, pp. 133–139, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. C. S. Ha, B. S. Joo, S. C. Kim, J. K. Joo, H. G. Kim, and K. S. Lee, “Estrogen administration during superovulation increases oocyte quality and expressions of vascular endothelial growth factor and nitric oxide synthase in the ovary,” Journal of Obstetrics and Gynaecology Research, vol. 36, no. 4, pp. 789–795, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Kauser and G. M. Rubanyi, “Gender difference in bioassayable endothelium-derived nitric oxide from isolated rat aortae,” American Journal of Physiology, vol. 267, no. 6, part 2, pp. H2311–H2317, 1994. View at Google Scholar · View at Scopus
  34. C. Adams, H. O. McCarthy, J. A. Coulter et al., “Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells,” Journal of Gene Medicine, vol. 11, no. 2, pp. 160–168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Jung, G. Hotter, J. L. Viñas, and A. Sola, “Cisplatin upregulates mitochondrial nitric oxide synthase and peroxynitrite formation to promote renal injury,” Toxicology and Applied Pharmacology, vol. 234, no. 2, pp. 236–246, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Mukundan, T. C. Resta, and N. L. Kanagy, “17-β estradiol independently regulates erythropoietin synthesis and NOS activity during hypoxia,” Journal of Cardiovascular Pharmacology, vol. 43, no. 2, pp. 312–317, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. V. Todorov, B. Gess, A. Gödecke, C. Wagner, J. Schräder, and A. Kurtz, “Endogenous nitric oxide attenuates erythropoietin gene expression in vivo,” Pflugers Archiv European Journal of Physiology, vol. 439, no. 4, pp. 445–448, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Ates, A. U. Yalcin, S. Yilmaz, T. Koken, and C. Tokyol, “Protective effect of erythropoietin on renal ischemia and reperfusion injury,” ANZ Journal of Surgery, vol. 75, no. 12, pp. 1100–1105, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. A. de Beuf, P. C. D'Haese, and A. Verhulst, “Epoetin delta as an antifibrotic agent in the remnant kidney rat: a possible role for transforming growth factor beta and hepatocyte growth factor,” Nephron—Experimental Nephrology, vol. 115, no. 3, pp. e46–e59, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. P. P. Dukes and E. Goldwasser, “Inhibition of erythropoiesis by estrogens,” Endocrinology, vol. 69, pp. 21–29, 1961. View at Google Scholar · View at Scopus
  41. W. Jelkmann, “Erythropoietin: structure, control of production, and function,” Physiological Reviews, vol. 72, no. 2, pp. 449–489, 1992. View at Google Scholar · View at Scopus